TOMI™ Expands Opportunity in US Hospital and Healthcare Markets With Amended EPA Registration

BEVERLY HILLS, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (OTCQB:TOMZ) (TOMI), a global bacteria decontamination and infection prevention company, announced the United States Environmental Protection Agency (EPA) has amended TOMI’s registration for its patented Binary Ionization Technology (BIT™) to include its effectiveness in disinfecting Clostridium difficile spores (C. diff)+, Methicillin Resistant Staphylococcus aureus (MRSA)**and influenza (H1N1)**.

Amended EPA Registration
Dr. Halden Shane, TOMI’s Chief Executive Officer, stated: “Our amended registration with the EPA significantly increases our market opportunity in the US hospital and healthcare channels. Through our extensive testing process with the EPA, we demonstrated BIT’s efficacy against a broad spectrum of pathogens*, MRSA**, H1N1** and C. diff spores+. The test protocols that TOMI passed for C. diff spores+ required 100% kill of the spores, three days in a row and demonstrated physical six-log kill (99.9999%) by destroying the cell wall of a C. diff spore+.

“SteraMist’s™ Environment unit offers complete room treatment of C. diff spores+ in just over 75 minutes for a 3,663.7 cubic foot room, less time is typically needed for smaller size rooms including application time, contact time, and aeration time, all of which allows for quick room disinfection and turnover. TOMI’s treatment time using our Environment unit may be the fastest of all other similar registered EPA fogging and misting equipment.

“Great for daily use, TOMI’s SteraMist™ surface unit goes above, beyond, under and around other disinfecting sprays and wipes. Terminal clean rooms may be treated in just 15 minutes for the average hospital room of 104 cubic meters, including rooms where MRSA** is suspect. Simply spray for five seconds per square foot for disinfection and walk away. When you re-enter the room, you can “smell the clean.” SteraMist™ is ideal for pandemic preparedness for listed organisms*. Overall our product requires no wipe, no rinse, leaves no residues, is a bleach and chlorine free formula, does not leave silver ions on surfaces or equipment, is easily incorporated in current cleaning procedures and does not contaminate the environment with any toxic by-products.

“Additionally, TOMI’s SteraMist™ BIT platform provides hospitals and healthcare facilities with a simple, quick and cost effective solution to reducing penalties associated with the Affordable Care Act and Medicare’s non-payment policy. We are very excited about the new opportunities in the US hospital and healthcare market as a result of our amended label, and we look forward to keeping you updated on our progress,” concluded Dr. Shane.

Infection is a Costly Issue for Healthcare Facilities
According to the National Center for Biotechnology Information (NCBI), approximately 1.7 million people per year in the US are infected with infections during a hospital stay and over 98,000 of those cases are fatal. Patients admitted to a hospital have a 5% chance of contracting an infection, increasing their stay by approximately 17.6 days. As more than two-thirds of infections in hospitals affect people with Medicare or Medicaid, this becomes a costly issue for healthcare facilities. The US hospital and healthcare systems spends approximately $35 billion per year, or $1,100 per patient admission to treat such infections.

The SteraMist BIT Platform Provides Solutions
TOMI deploys BIT via its SteraMist line of products, which utilizes a proprietary system that kills and inactivates bacteria, viruses, and mold spores leaving surfaces and rooms free of pathogens* that are typically found in hospitals and healthcare environments. Most recently, its proprietary BIT has demonstrated its effectiveness in disinfecting Clostridium difficile (C. diff) spores+, Methicillin Resistant Staphylococcus aureus (MRSA) **, Pseudomonas* and influenza (H1N1) **, which are three of the most prevalent, harmful and costly pathogens facing healthcare systems worldwide.

TOMI received an EPA registration (no. 90150-2) for BIT in June 2015, for use as a healthcare-hospital disinfectant. TOMI’s SteraMist BIT is currently registered in 35 states to date. The SteraMist BIT brand of products includes the SteraMist Surface Unit, which is a handheld, point-and-spray application, and SteraMist Environment System, which is a complete room fogging system. More information on TOMI’s complete suite of SteraMist BIT products can be found at or below.

Source Materials

+Clostridium difficile spores (C. diff) (ATCC# 43598) test conducted with SteraMist™ Environment System.

** Methicillin Resistant Staphylococcus aureus (MRSA), Pseudomonas and influenza (H1N1) test conducted with SteraMist Surface Unit.

* Pathogens: SteraMist disinfects against Clostridium difficile spores (C. diff) (ATCC# 43598), Methicillin Resistant Staphylococcus aureus (MRSA) (ATCC# 33592), and Influenza A (H1N1) virus (ATCC VR-1469).

About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQB:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface decontamination through manufacturing, sales and licensing of our premier platform of Hydrogen Peroxide based products that uses Binary Ionization Technology® (BIT), a state of the art technology for the production of its health care–hospital disinfectant aerosol mist represented by the TOMI™ SteraMist™ brand.

TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, biosafety labs, clean rooms, pharmaceutical manufacturing, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit or contact us at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

INVESTOR RELATIONS CONTACT: Becky Herrick & Kirsten Chapman LHA (IR Agency) (415) 433-3777 MEDIA RELATIONS CONTACT: Aaron Loveland VP of Marketing and Public Affairs (240) 672-6263

Source:TOMI Environmental Solutions, Inc.